Dr. Albers joined Astrocyte Pharmaceutical’s Scientific Advisory Board in April of 2019. Dr. Gregory W. Albers is the director of the Stanford Stroke Center, a position he has held since co-founding the center in 1992. Dr. Albers’ primary research focus is the diagnosis, management, and prevention of ischemic stroke. Dr. Albers and his team use advanced imaging technology to expand the treatment window for ischemic stroke. He has been the principal investigator of all 3 DEFUSE studies, which were NIH-funded research projects that clarified the evolution of brain ischemia and led to extending the treatment window for stroke to 24 hours in 2018. Dr. Albers has authored more than 450 articles on topics related to cerebrovascular disease in peer-reviewed journals, and is the Chairman of the Stroke Treatment Academic Industry Roundtable (STAIR). He was instrumental in the development of RAPID, a software platform that interprets brain scans and helps clinicians decide on appropriate treatments for ischemic stroke; studies that selected patients with RAPID have reported the highest recovery rates ever achieved.
Dr. Gregory W. Albers graduated from the University of California, San Diego School of Medicine and completed his medical training with an internship (internal medicine), residency (neurology), and fellowship (cerebrovascular disease) at the Stanford University Medical Center. Dr. Albers joined the Stanford University faculty in 1989. In 2011, Dr. Albers received the American Heart Association’s prestigious David G. Sherman Award for Outstanding Contributions to Stroke Research.
